Overview

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To define the effective dose and tolerability of levetiracetam in individuals with Restless Legs Syndrome (RLS). It is hypothesized that levetiracetam will be well tolerated, safe and effective in treating the symptoms of RLS.
Phase:
Phase 2
Details
Lead Sponsor:
Sleep Health Centers
Collaborator:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam